HOME >> MEDICINE >> NEWS
Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients

is developing advanced drugs and vaccines for cancer and infectious diseases. Maxim's focus is to develop novel products that include pharmacoeconomic and disease management benefits such as out-patient therapy, improved clinical efficacy, higher level of safety, cost-effective treatment and improved patient compliance. The Company has initiated three Phase III cancer clinical trials for its lead product Maxamine in the U.S., Europe and Australia for malignant melanoma and acute myelogenous leukemia. Phase II trials of Maxamine Therapy are ongoing or planned for other cancer indications such as renal cell carcinoma and prostate adenocarcinoma. The Company also plans to test Maxamine Therapy in a Phase II clinical trial for the treatment of hepatitis C patients. The Company's secondary platform technology, MaxVax®, now in preclinical development, utilizes a mucosal vaccine carrier/adjuvant system for a broad range of infectious diseases. The Company expects to commercialize its technologies through a combination of in-house development and collaborative agreements with pharmaceutical companies.

This news release contains certain forward-looking statements that involve risks and uncertainties. The Company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include, but are not limited to, those discussed under "Risk Factors" and elsewhere in the Company's Annual Report on Form 10-K for the year ended September 30, 1997 and the Company's Registration Statement on Form S-3 (File No. 333-65011), each as amended through the date hereof, as filed with the Securities and Exchange Commission, including the uncertainties associated with patent protection, the risk that products that appeared promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the risk that clinical trials will not commence when planned, and the risk that the Company wi
'"/>

Contact: Amy Flood
a.flood@noonanrusso.com
415-677-4455 x211
Noonan/Russo Communications
7-Dec-1998


Page: 1 2 3 4 5 6

Related medicine news :

1. Elan and Biogen Idec announce results from Phase III maintenance trial of Antegren
2. Phase II trial of anthrax vaccine to begin
3. NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed
4. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
5. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
6. Penn researchers announce results of Phase I trial using combretastatin drug
7. Anti-cocaine vaccine produces antibodies and is shown to be safe in Phase 1 study conducted by Yale researcher
8. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
11. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/7/2018)... , ... September 07, 2018 , ... Start your engines ... 12 different sports experiences from which to choose. Pedal power is the name of ... Drag Strip Experience or turning left on the miniature Indianapolis Motor Speedway oval. , ...
(Date:9/2/2018)... ... September 02, 2018 , ... Eaton ... social change. The hotel itself, which opened this week, inspires creativity and innovation ... or more. , Eaton Hotel DC currently features 209 hotel rooms, a wellness ...
(Date:8/31/2018)... ... 31, 2018 , ... Becker's Healthcare is pleased to release ... community hospitals as well as facilities affiliated with large health systems. Some hospitals ... cities. The hospitals continue to grow in many communities, opening new departments and ...
(Date:8/31/2018)... ... 2018 , ... Nitro Circus hosted the inaugural A Night to Live Like ... gathering to celebrate the life of Erik Roner, world-renowned skier, skydiver and a founding ... and their two small children, Oskar (8) and Kasper (4). A portion of the ...
(Date:8/31/2018)... ... August 31, 2018 , ... ... a small molecule drug discovery and development firm based in the Frederick ... to develop a first-in-class therapeutic targeting rare immune-mediated blood disorders, beginning with ...
Breaking Medicine News(10 mins):
(Date:9/1/2018)... Sedona, AZ (PRWEB) , ... September 01, 2018 , ... ... looking to optimize your health, research has shown a balanced diet is key. ... seeking ways to receive the highest form of nutrition to improve or continue their ...
(Date:9/1/2018)... ... September 01, 2018 , ... The 2017 sustainability ... the company’s continued efforts to “Create a Better Future” through a focus on ... natural resources. , “2017 was a positive year for Shaw, as we ...
(Date:8/31/2018)... ... August 31, 2018 , ... The Centers for ... 22 years of expertise in delivering comprehensive wellness engagement solutions, has been selected ... Onlife Health will receive a $40,000 grand prize for its winning proposal, Closing ...
Breaking Medicine Technology:
Cached News: